245 related articles for article (PubMed ID: 28327155)
1. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
Tu M; Li H; Lv N; Xi C; Lu Z; Wei J; Chen J; Guo F; Jiang K; Song G; Gao W; Miao Y
Mol Cancer; 2017 Mar; 16(1):66. PubMed ID: 28327155
[TBL] [Abstract][Full Text] [Related]
2. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
Bhutia YD; Hung SW; Krentz M; Patel D; Lovin D; Manoharan R; Thomson JM; Govindarajan R
PLoS One; 2013; 8(1):e53436. PubMed ID: 23335963
[TBL] [Abstract][Full Text] [Related]
3. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
Xia G; Wang H; Song Z; Meng Q; Huang X; Huang X
J Exp Clin Cancer Res; 2017 Aug; 36(1):107. PubMed ID: 28797284
[TBL] [Abstract][Full Text] [Related]
4. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.
Lu H; Lu S; Yang D; Zhang L; Ye J; Li M; Hu W
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30777929
[TBL] [Abstract][Full Text] [Related]
5. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Oncogene; 2004 Feb; 23(8):1539-48. PubMed ID: 14661056
[TBL] [Abstract][Full Text] [Related]
6. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
[TBL] [Abstract][Full Text] [Related]
7. ARID1A promotes chemosensitivity to gemcitabine in pancreatic cancer through epigenetic silencing of RRM2.
Li W; Chen Q; Gao W; Zeng H
Pharmazie; 2022 Sep; 77(7):224-229. PubMed ID: 36199183
[TBL] [Abstract][Full Text] [Related]
8. Vasohibin 2 promotes malignant behaviors of pancreatic cancer cells by inducing epithelial-mesenchymal transition via Hedgehog signaling pathway.
Zhang Y; Xue X; Zhao X; Qin L; Shen Y; Dou H; Sun J; Wang T; Yang DQ
Cancer Med; 2018 Nov; 7(11):5567-5576. PubMed ID: 30318866
[TBL] [Abstract][Full Text] [Related]
9. RETRACTED: Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer.
Duxbury MS; Ito H; Benoit E; Zinner MJ; Ashley SW; Whang EE
Surgery; 2004 Aug; 136(2):261-9. PubMed ID: 15300189
[TBL] [Abstract][Full Text] [Related]
10. E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2.
Liu Q; Song C; Li J; Liu M; Fu L; Jiang J; Zeng Z; Zhu H
Med Oncol; 2022 Jun; 39(9):124. PubMed ID: 35716217
[TBL] [Abstract][Full Text] [Related]
11. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
Xie H; Lin J; Thomas DG; Jiang W; Liu X
Int J Clin Exp Pathol; 2012; 5(4):347-55. PubMed ID: 22670179
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.
Lai IL; Chou CC; Lai PT; Fang CS; Shirley LA; Yan R; Mo X; Bloomston M; Kulp SK; Bekaii-Saab T; Chen CS
Carcinogenesis; 2014 Oct; 35(10):2203-13. PubMed ID: 24879635
[TBL] [Abstract][Full Text] [Related]
14. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
15. Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640.
Lewis CS; Voelkel-Johnson C; Smith CD
Oncotarget; 2016 Sep; 7(37):60181-60192. PubMed ID: 27517489
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction.
Chen P; Wu JN; Shu Y; Jiang HG; Zhao XH; Qian H; Chen K; Lan T; Chen CG; Li J
Clin Sci (Lond); 2018 Jul; 132(13):1417-1433. PubMed ID: 29853661
[TBL] [Abstract][Full Text] [Related]
17. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
Nakahira S; Nakamori S; Tsujie M; Takahashi Y; Okami J; Yoshioka S; Yamasaki M; Marubashi S; Takemasa I; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Int J Cancer; 2007 Mar; 120(6):1355-63. PubMed ID: 17131328
[TBL] [Abstract][Full Text] [Related]
18. Vasohibin-2 plays an essential role in metastasis of pancreatic ductal adenocarcinoma.
Iida-Norita R; Kawamura M; Suzuki Y; Hamada S; Masamune A; Furukawa T; Sato Y
Cancer Sci; 2019 Jul; 110(7):2296-2308. PubMed ID: 31074083
[TBL] [Abstract][Full Text] [Related]
19. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
Liu F; Gore AJ; Wilson JL; Korc M
PLoS One; 2014; 9(1):e84982. PubMed ID: 24409315
[TBL] [Abstract][Full Text] [Related]
20. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.
Liu J; Ma J; Wu Z; Li W; Zhang D; Han L; Wang F; Reindl KM; Wu E; Ma Q
BMC Cancer; 2014 Sep; 14():686. PubMed ID: 25240403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]